Analysis: ChemoMetec could raise its guidance again, but…
Denmark’s ChemoMetec has already raised its full-year guidance twice this year, but a new analysis from Aktieinfo points to another hike, although the investment portal issues a warning for short-term investors.
BY STEFAN SINGH KAILAY
A change in distribution strategy seems to have paid off for Danish gene analysis firm ChemoMetec. Due to a greater focus on its own distribution network, the company has been able to raise its full-year guidance twice in the current year, and an analysis from investment portal Aktieinfo suggests another guidance hike could be on the cards.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
ChemoMetec: Changes have bigger impact than we thought
For abonnenter
ChemoMetec wants to increase pace of US growth
For abonnenter
ChemoMetec chief: Clear expectation of continued growth
For abonnenter
